Pushkal Garg Sells 1,561 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,561 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the transaction, the chief marketing officer now directly owns 13,537 shares in the company, valued at $3,454,236.29. The trade was a 10.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.67, for a total value of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Trading Up 0.2 %

ALNY opened at $250.51 on Thursday. The firm has a market cap of $32.43 billion, a P/E ratio of -115.44 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a 50-day moving average of $253.89 and a 200 day moving average of $263.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALNY. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. Larson Financial Group LLC boosted its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 73 shares during the period. Hollencrest Capital Management purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $33,000. Finally, OFI Invest Asset Management purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ALNY. Scotiabank reduced their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research note on Friday, February 14th. Piper Sandler restated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research note on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, February 14th. Finally, StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.